StockData
CytomX Therapeutics, Inc. logo

CytomX Therapeutics, Inc. (CTMX) income statement

CTMXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 8/30
$1.88−0.06 (-3.09%)

Close on Nov 18, 2026Market cap $409.65MP/E –Yield –

CytomX Therapeutics, Inc. income statement

Ratios

Latest available, balances at Jun 30, 2026

Profitability, TTM

Gross margin
–
Operating margin
-476.2%
Net margin
-435.2%
Return on equity, FY2025
-35.2%

Financial strength

Current ratio
9.36
Debt to equity
–
Debt to assets
–
Cash to current liabilities
43.2%

Valuation

P/E ratio
–
Price to sales
22.38
Price to book
1.36
Dividend yield
–

See a number that looks wrong?